RenovoRx is developing innovative solutions for targeted delivery of fluids to selected sites in the peripheral vascular system.
RenovoRx is a developing innovative solutions for targeted delivery of fluids, including diagnostic and therapeutic agents, to selected sites in the peripheral vascular system. RenovoRx received FDA clearance for the RenovoCath™ RC120 and is currently introducing this innovative technology to the clinical market.RenovoRx has a motivated Management Team with broad experience and an exciting vision for the future of targeted delivery. The company also has a broad Advisory Board of interventional radiologists, surgical oncologists and gastroenterologists that guide the company's clinical development strategies. RenovoRx is backed by a strong Board of Directors committed to long-term, continuous support of the company, whose members provide critical expertise in the medical and biotechnology industry and the visionary thinking to succeed.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 19, 2018 | Series D | $8.30M | 1 | Boston Scientific | — | Detail |
Dec 7, 2015 | Series C | — | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Boston Scientific | Yes | Series D |
Next Wave/Portfolia Angel Fund | — | Series C |